Trevena, Inc.

TRV250

Acute Migraine

Migraine is a common and debilitating brain disorder that remains poorly treated for many patients. There are approximately 650 million headaches treated each year* and approximately 1.2 million emergency room visits due to migraines.

Approximately 33.8 million people suffer from either episodic or chronic migraine. Of those, an estimated 20% to 30% either do not respond to or cannot tolerate the market-leading triptan drug class.

The total migraine drug market is approximately $3.45 billion and is projected to continue growing at a rate of 12% per year through 2027.1

About TRV250

Trevena is developing TRV250 for the acute treatment of migraine. Unlike currently approved migraine therapies, it targets the delta-opioid receptor (delta receptor). Using a novel mechanism of action, TRV250 preferentially engages the signaling pathway responsible for efficacy, with reduced activation of the signaling pathway associated with delta receptor-mediated adverse effects.

The delta receptor is located throughout the brain and plays a role in regulating pain, mood, and anxiety.2 However, the therapeutic potential of this receptor in CNS-mediated diseases has remained largely untapped, due to debilitating adverse effects associated with this receptor target.3 The discovery innovations made by Trevena have yielded TRV250, a compound that, in non-clinical and early clinical studies, appears to reduce the risk of such adverse effects, thus opening the possibility of investigating the therapeutic benefits of a delta receptor agonist in humans.4

Program Molecular Target Therapeutic Target Current Phase PC PH1 PH2 PH3 NDA Approved
TRV250 Delta receptor Acute migraine PH1 Oral/Subcutaneous PC complete PH1 in progress PH2 not started PH3 not started NDA not started Approved not started
TRV250 is an Investigational Product not approved by FDA for sale or distribution in the US.

*Chronic migraine defined as >15 attacks per month.

  1. Decision Resources, Pharmacor migraine market landscape and forecast 2018.
  2. Chu Sin Chung P, Kieffer BL. Delta opioid receptors in brain function and diseases. Pharmacol Ther. 2013 Oct;140(1):112-20.
  3. Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E, Befort K, Kieffer BL. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Behav Brain Res. 2015 Feb 1;278:429-34.
  4. Fossler MJ, Schmith V, Greene SA, et al. CNS Drugs. 2020;34(8):853-865.